Search PubMed⌕ Search

Biomedical subjects

B C Turnbull

Publications and source records attributed to B C Turnbull.

7 recordsLinked to original sources
PubMed1982

Locoid vs betnovate lotion in the treatment of seborrhoeic and atopic dermatitis of the scalp.

In a randomised, double-blind clinical trial, the relative efficacy of Locoid scalp lotion and Betnovate scalp application was assessed in the treatment of 30 patients, 15 in each treatment group, suffering from seborrhoeic or atopic dermatitis of the scalp. Both therapies produced a statistically significant improvement and clearance of the lesions by the end of the four weeks of treatment. Slight differences were observed in favour of Betnovate with respect to global efficacy but this difference was not statistically significant. Side-effects were not spontaneously complained of by any of the 30 patients but six admitted experiencing a stinging or burning sensation (four with Locoid and two with Betnovate) when asked specifically as to the occurrence of these side-effects.

Adolescent↗
PubMed1982

Tetracycline and minocycline in the management of non-gonococcal urethritis: a comparison.

A clinical trial compared the relative efficacy of tetracycline hydrochloride 250 mg qid and minocycline hydrochloride 100 mg bid given for an initial period of ten days to 59 patients suffering from non-gonococcal urethritis (NGU). Those patients with persistent symptoms or signs on completion of the initial course were given a second course for a further ten days at the same dosage. The treatments were equivalent. A significant number of patients not clinically cured after one course of treatment responded satisfactorily to a second course.

Adolescent↗
PubMed1982

Melanoma.

Explore the source record for details and available documents.

Age Factors↗
PubMed1981

A multicentre trial of Zostrum (5 percent idoxuridine in dimethyl sulphoxide) in herpes zoster.

Forty-six patients with herpes zoster were randomised into two groups treated with DMSO alone and 5 percent IDU in DMSO, provided that treatment started within 48 hours of the appearance of a rash. In the IDU group the interval before pain improved was significantly shorter than in the control DMSO group, and significantly fewer new vesicles developed at the three day follow up in the active group compared with the control group. These findings are in agreement with previously published work and confirm the usefulness of Zostrum (5 percent IDU in DMSO) in the treatment of herpes zoster.

Administration, Topical↗